Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 376
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Mark Barrett | Chief Business Officer | N/A | N/A | N/A |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 7.